Johnson & Johnson (NYSE:JNJ) Shares Down 1.7% – Time to Sell?

Shares of Johnson & Johnson (NYSE:JNJ) fell 1.7% on Monday . The stock traded as low as $248.63 and last traded at $248.83. Approximately 8,109,336 shares were traded during trading, a decline of 4% from the average daily volume of 8,458,165 shares. The stock had previously closed at $253.04.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported robust Q2 2026 results, beating expectations on both earnings and revenue, and raised its full-year 2026 guidance, reinforcing confidence in its growth outlook. Article: Should You Buy, Sell or Hold J&J’s Stock Post a Robust Q2 Performance?
• Positive Sentiment: Recent coverage highlighted JNJ as one of the large-cap names quietly trading near 52-week or all-time highs, suggesting investors are rotating into defensive, high-quality stocks outside of the AI trade. Article: 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama (JNJ)
• Positive Sentiment: Analysts and commentators remain constructive on J&J’s long-term profile, pointing to its diversified business, strong balance sheet, and durable dividend history as reasons the stock can continue compounding. Article: Guggenheim Reiterates Buy Rating for Johnson & Johnson (NYSE:JNJ)

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a report on Wednesday. Barclays lifted their target price on Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 15th. Freedom Capital raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday. Morgan Stanley upped their target price on Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Scotiabank reissued an “outperform” rating and set a $305.00 price objective on shares of Johnson & Johnson in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $265.30.

Johnson & Johnson Trading Down 1.7%

The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The business has a fifty day simple moving average of $239.82 and a 200 day simple moving average of $234.82. The company has a market cap of $598.99 billion, a price-to-earnings ratio of 28.83, a P/E/G ratio of 2.39 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter in the previous year, the company posted $2.77 EPS. The business’s revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 11.68 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s payout ratio is currently 62.11%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds have recently made changes to their positions in the business. Blueline Advisors LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter worth about $25,000. Cresta Advisors Ltd. purchased a new stake in Johnson & Johnson in the fourth quarter valued at approximately $26,000. DecisionPoint Financial LLC increased its position in Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after purchasing an additional 75 shares during the last quarter. Bay Harbor Wealth Management LLC raised its stake in Johnson & Johnson by 49.0% during the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after purchasing an additional 49 shares during the period. Finally, Family CFO Inc purchased a new position in Johnson & Johnson during the fourth quarter worth approximately $31,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.